Posts tagged Denver Boulder
CU : Some good news for doggie lovers
Dec 11th
clinical study to treat canine pain
A University of Colorado Boulder professor and her biomedical spinoff company Xalud Therapeutics Inc. of San Francisco are teaming up with a Front Range veterinarian to conduct a clinical study targeting an effective treatment for dogs suffering from chronic pain.
Distinguished Professor Linda Watkins of CU-Boulder’s psychology and neuroscience department said the study involves treating ailing dogs with a gene therapy using Interleukin-10, or IL-10, a protein and anti-inflammatory that both dogs and humans produce naturally. Watkins is working with veterinarian Robert Landry of Mountain Ridge Animal Hospital and Pain Management Center in Lafayette, who will be treating canine patients suffering from chronic and painful conditions, some of which already are being treated with various other medications with limited success.

Animals perceive and experience several levels of pain that are similar to humans, and chronic pain can be debilitating and also shorten the lives of pets, said Landry, one of only a handful of credentialed American Academy of Pain Management practitioners in Colorado. Landry currently is seeking Denver-Boulder area pet owners who have dogs suffering from chronic pain and who might be interested in participating in the study, which is free.
The new study is driven by research spearheaded by Watkins indicating a type of cell known as glial cells found in the nervous system of mammals plays a key role in pain. Under normal conditions, glial cells act as central nervous system “housekeepers,” cleaning up cellular debris and providing support for neurons, said Watkins. But glial cells also can play a pivotal role in pain enhancement by exciting neurons that both transmit pain signals and release a host of chemical compounds that cause problems like chronic neuropathic pain and other medical issues.
The team will use Xalud’s lead product candidate, XT-101, a gene therapy that harnesses the power of the potent anti-inflammatory IL-10 to normalize glial activity and eliminate neuropathic pain for up to 90 days with a single injection.

The gene therapy based on IL-10 has a number of advantages, including suppressing glial activity in the spinal cord, stimulating tissue regeneration and growth, decreasing the production of pro-inflammatory substances and increasing the production of anti-inflammatory substances, Watkins said. Landry and Watkins also have been working with the American Kennel Club on potential funding for additional clinical studies involving the treatment of chronic pain in dogs, said Watkins.
“We have already tested this new therapy in two pet dogs, and both have had remarkable reversals of their pain for long durations after a single injection of the therapeutic,” she said. “Our early peek at the potential of this therapeutic treatment in dogs shows essentially the same positive effects we have seen in laboratory rats used in our studies that have been treated with the therapy.”
Watkins said demonstrating the efficacy and safety of the new gene therapy in a second species of mammal is important in terms of moving it forward to eventually meet FDA regulations for human clinical trials.
In addition to studying what triggers glial cells to become activated and begin releasing pain-enhancing substances and ways to control chronic pain, Watkins and her research team recently discovered that clinically prescribed opioids also activate glial cells and cause them to release pain-enhancing substances. “Our ultimate goal is to find a means by which clinical pain control can be improved so as to relieve human suffering,” she said.
To contact Landry about possible participation in the study by family dogs suffering chronic pain and that might benefit from the experimental treatment, call the Mountain Ridge Animal Hospital at 303-665-4852.
For more information on CU-Boulder’s psychology and neuroscience department visit http://psych-www.colorado.edu/. For more information on Xalud Therapeutics Inc. visit http://www.xaludthera.com/. For more information on Mountain Ridge Animal Hospital visit http://www.mountainridgevet.com/.
[includeme src=”http://c1n.tv/boulder/media/bouldersponsors.html” frameborder=”0″ width=”670″ height=”300″]
–
CU research propels “Blade Runner” to Olympics
Jul 11th
Professors Rodger Kram and Alena Grabowski of the integrative physiology department have been involved in several studies analyzing the performance of amputee athletes, including Pistorius, who use blade-like, carbon fiber leg prostheses in track events. In 2007, Pistorius was barred from international competition by officials from the International Association of Athletics Federations, or IAAF, who ruled his Cheetah Flex-Foot leg prostheses conferred him an advantage over other runners.
Barred from competition, then exonerated
The decision was based in large part on a German study commissioned by the IAAF. However, data presented in April 2008 by a team that included Kram and Grabowski to the Court of Arbitration for Sport in Lausanne, Switzerland — an international group set up to settle disputes in sports — showed Pistorius gained no physiological advantage from the Cheetah prostheses over competitors. The team’s evidence and testimony played a key role in overturning the decision, allowing Pistorius to compete in able-bodied events.

The Blade Runner good to go
“The methodology of the German study that involved measuring Oscar’s oxygen consumption while running was flawed,” said Kram, who has been measuring the oxygen consumption of runners since 1983. “When we had a chance to properly measure Oscar we found that while he is quite economical in oxygen consumption compared to your average Joe, his values are well within what would be expected for a high-caliber athlete.”
At the arbitration hearings in Switzerland, Kram also argued that if a prosthetic device provides a mechanical advantage, it would very likely provide an energetic or physiological advantage. “Since there is no energetic advantage, it infers that the prostheses do not provide a mechanical advantage either,” said Kram.
Another chance
Although Pistorius subsequently failed to make the 2008 Olympic team, he was selected by South Africa’s Olympic Committee last week to run in both the individual 400 meters and a leg of the 4×400 meter relay in the 2012 Olympic Games in London, which begin on July 27. “I was delighted that Oscar was selected,” said Kram. “I was sure he’d be named to the 4×400 meter relay, but being named to the 400-meter individual event was a surprise.”
Since 2008, the research team involving CU-Boulder has continued its studies. In a 2010 study led by Grabowski, researchers used force-measuring treadmills to analyze the biomechanics of unilateral amputees — those with one amputated leg — over a wide range of running speeds. The team found the force produced by the prosthetic, carbon fiber leg was 9 percent less than that of the unaffected leg. “Applying force to the ground is crucial in sprinting events,” said Grabowski.
“We inferred that running-specific prostheses impair force generation and likely limit top sprinting speed,” said Grabowski, who received her doctorate under Kram in 2008 and recently returned to CU-Boulder as a research faculty member after doing postdoctoral work at the Massachusetts Institute of Technology. Other authors on the 2010 paper included Kram, Craig McGowan of the University of Idaho, William McDermott of the Orthopedic Specialty Hospital in Murray, Utah, and Hugh Herr of MIT.
In a 2012 paper by the same group and led by McGowan, the leg stiffness of Paralympic sprinters with both unilateral and bilateral leg amputations was compared to non-amputee sprinters across a range of speeds. The team found leg stiffness remained constant or increased with speed in non-amputees but decreased in sprinting amputees.
“During running, the leg behaves much like a spring, and the stiffness of the leg greatly influences the overall mechanics of the runner,” said Grabowski. “The study indicates that the prosthetic device limits the ability of a sprinter to change their leg stiffness during running.” In the future, she said, researchers may be able to design a prosthetic device with “adaptive stiffness” that would more accurately emulate the mechanics of a biological ankle during sprinting.
Research fueled by veterans needs
Grabowski, whose work is funded by the Veterans Administration, is particularly interested in designing better prosthetic ankle devices for military veterans or those on active duty who have undergone amputations. In collaboration with the Denver Department of Veterans Affairs, Grabowski is beginning a research effort to further develop battery-powered ankle-foot prostheses for walking and running. Such prostheses have the potential to restore mobility to users similar to the mobility they had prior to amputation, she said.
The research team is interested in locating potential test subjects in the Denver-Boulder area with leg amputations to participate in lab studies. “CU-Boulder is actively pursuing research that aims to improve the lives of amputees, particularly veterans and current military personnel,” she said. Potential study candidates can contact Grabowski at Alena.Grabowski@colorado.edu.
Research in Kram’s Locomotion Laboratory on the CU-Boulder campus goes far beyond athletics. Collaborating faculty and students are targeting the energetic costs of walking, including uphill and downhill walking in older adults; the energetics of passive cycling to treat and prevent obesity and heart disease; and studies on animal locomotion, including kangaroos, tortoises and elephants.
For more information on the CU-Boulder Locomotion Laboratory visit http://www.colorado.edu/intphys/research/locomotion.html. For more information on CU’s integrative physiology department visithttp://www.colorado.edu/intphys/.























